Diagnostic accuracy of anti-MCV and anti-CCP antibodies in rheumatoid arthritis

Lee, Young Ho; Bae, Sang Cheol; Song, Gwan Gyu

doi:10.1007/s00393-015-1598-x

Cited by 36 publications

(15 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a previous meta-review, which summarized 12 studies on the diagnostic accuracy of anti-CCP assays, the area under the curve for the discrimination of 1988 patients with RA from 1740 disease controls without RA was 0.817 based on pooled sensitivities and specificities of 0.634 and 0.955, respectively. 17 Our study has a limitation in that we could not estimate diagnostic performance of the evaluated assays according to RA stages because we were unable to obtain sufficient clinical information on patients with RA, including the degree of arthralgia and the number of affected joints because of the retrospective study design. We could not investigate the correlation between results of the anti-CCP assays and clinical manifestations either.…”

Section: Discussionmentioning

confidence: 97%

Laboratory and Clinical Performance of the ADVIA Centaur Anticyclic Citrullinated Peptide Assay for Rheumatoid Arthritis Diagnosis

Kim

Park

et al. 2018

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

Laboratory and Clinical Performance of the ADVIA Centaur Anticyclic Citrullinated Peptide Assay for Rheumatoid Arthritis Diagnosis

Kim

Park

et al. 2018

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

show abstract

“…In early RA, anti-MCV sensitivity and specificity (64% and 97%) are higher than those of RF [99]. A recent meta-analysis, which included a total of 12 studies and 2003 RA patients, demonstrated a higher sensitivity of anti-MCV (68.6%) than anti-CCP (61.7%) in the diagnosis of RA, although anti-MCV specificity (94.2%) remained lower than that of anti-CCP (97.1%) [100]. High levels of anti-MCV antibodies seem to predict a rapid erosive disease in early RA and have been associated with active disease and worst outcomes [101,102].…”

Section: Additional Autoantibodiesmentioning

confidence: 97%

Autoantibodies in inflammatory arthritis

Conigliaro

Chimenti

Triggianese

et al. 2016

Autoimmunity Reviews

100

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a systemic chronic inflammatory disease characterized by extensive synovitis resulting in erosions of articular cartilage and marginal bone with joint destruction. The lack of immunological tolerance in RA represents the first step toward the development of autoimmunity. Susceptible individuals, under the influence of environmental factors, such as tobacco smoke, and silica exposure, develop autoimmune phenomena that result in the presence of autoantibodies. HLA and non-HLA haplotypes play a major role in determining the development of specific autoantibodies differentiating anti-citrullinated antibodies (ACPA)-positive and negative RA patients. Rheumatoid factor (RF) and ACPA are the serological markers for RA, and during the preclinical immunological phase, autoantibody titers increase with a progressive spread of ACPA antigens repertoire. The presence of ACPA represents an independent risk factor for developing RA in patients with undifferentiated arthritis or arthralgia. Moreover, anti-CarP antibodies have been identified in patients with RA as well as in individuals before the onset of clinical symptoms of RA. Several autoantibodies mainly targeting post-translational modified proteins have been investigated as possible biomarkers to improve the early diagnosis, prognosis and response to therapy in RA patients. Psoriatic arthritis (PsA) is distinguished from RA by infrequent positivity for RF and ACPA, together with other distinctive clinical features. Actually, specific autoantibodies have not been described. Recently, anti-CarP antibodies have been reported in sera from PsA patients with active disease. Further investigations on autoantibodies showing high specificity and sensibility as well as relevant correlation with disease severity, progression, and response to therapy are awaited in inflammatory arthritides

show abstract

“…In our patient's case, she had a history of RA for many years and her serologic testing showed a markedly elevated RF and anti-CCP to support RA as an accurate pre-existent diagnosis [9]. In the current case, no biopsy was performed to confirm diagnosis because of the high clinical suspicion of RA pachymeningitis and risks outweighed the benefits in a clinically improving patient.…”

Section: Discussionmentioning

confidence: 61%

When the plot thickens: a rare complication of rheumatoid arthritis

Scheitel

Ives

Nasr

et al. 2019

Journal of Community Hospital Internal Medicine Perspectives

View full text Add to dashboard Cite

Introduction : Rheumatoid arthritis (RA) is a common illness with many extraarticular manifestations. Rheumatoid pachymeningitis is a rare neurologic complication of this common disease. Here in we present a patient with longstanding RA who developed this uncommon complication. Case description : A 75-year-old woman with longstanding RA presented to the clinic with multiple seizure-like spells per day. Upon admission to the hospital, brain MRI showed enhancement of the meninges. After an extensive workup for possible other infectious or inflammatory causes, the patient was diagnosed with rheumatoid pachymeningitis. Conclusion : Rheumatoid pachymeningitis is a rare complication of RA that usually occurs late in the disease course. It may have many neurologic manifestations include mimicking seizure or stroke and must be considered in patients with RA presenting with neurologic symptoms. Pachymeningitis is treated distinctly from articular RA, so early recognition can lead to appropriate treatment.

show abstract

Diagnostic accuracy of anti-MCV and anti-CCP antibodies in rheumatoid arthritis

Abstract: Our meta-analysis demonstrates that anti-MCV is more sensitive but less specific, and has lower diagnostic accuracy than anti-CCP in RA, although anti-MCV and anti-CCP showed comparable high PLRs.

Cited by 36 publications

References 42 publications

Laboratory and Clinical Performance of the ADVIA Centaur Anticyclic Citrullinated Peptide Assay for Rheumatoid Arthritis Diagnosis

Laboratory and Clinical Performance of the ADVIA Centaur Anticyclic Citrullinated Peptide Assay for Rheumatoid Arthritis Diagnosis

Autoantibodies in inflammatory arthritis

When the plot thickens: a rare complication of rheumatoid arthritis

Contact Info

Product

Resources

About